Growing number of consumers rate Rx drugs online

Share this article:

Over 60 million adults in the US are using social media applications for healthcare online, and many are speaking directly about products, according to a new Manhattan Research report.

Websites like iGuard.org, DailyStrength.org and PatientsLikeMe.com are garnering thousands of comments and reviews on drugs and treatments. On DailyStrength.org, over 9,000 consumers have written about Pfizer's Zoloft, with comments ranging from side effects (“worked but gained a tremendous amount of weight!”), to off-label uses, such as pre-menstrual syndrome (“yes, this has been a help”).

Without clear guidelines from the FDA, manufactures will have to decide how best to monitor, solicit or respond to reviews and comments in these forums, the report said.

According to Craig Audit, vice president, US regulatory affairs, marketing products at Sanofi-Aventis, most adverse events reported on independent websites or on blogs don't sufficiently identify the safety signals of a drug, and should not be submitted to the FDA. Each company must decide what actions mesh best with the prevailing corporate culture. “What's your tolerance of uncertainty?” asked Audit at a conference on digital pharma in October.

Consumers commenting on products online is not all bad for manufacturers, since it provides unsolicited information to marketers, noted Alan Minsk, partner and chair of the food & drug practice team at Arnall Golden Gregory LLP, at the conference.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...